Amnestic Mild Cognitive Impairment
22
5
6
8
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
18.2%
4 terminated out of 22 trials
66.7%
-19.8% vs benchmark
5%
1 trials in Phase 3/4
75%
6 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (22)
Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History
Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia
Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment
Sleep Interventions and Neurocognitive Outcomes
Noninvasive Brain Stimulation on Memory in Individuals With Mild Cognitive Impairment and History of Brain Injury
Training Response Artificial Intelligence Network (TRAIN)
mSIM: Mobile Simultaneous Aerobic Exercise and Memory Training Intervention for Amnestic Mild Cognitive Impairment
Modified Ketogenic Diet in Amnestic Mild Cognitive Impairments
The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)
MRI Guided Closed-loop TMS-EEG
COG-REAGENT: COGnitive tRaining in patiEnts With Amnestic Mild coGnitive impairmENT
Interactive Stepping Exercise on Memory
Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)
CTA-MCI: Cognitive Control Training in Patients With Amnestic Mild Cognitive Impairment(CTA-MCI)
Recollection Training in Healthy Older Adults and Older Adults With Amnestic Mild Cognitive Impairment
An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)
[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)
A Combined Training Program for Veterans With Amnestic Mild Cognitive Impairment
Effect of AQW051 in Patients With Memory Impairment
Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment